Hamburg – CMS has successfully advised longstanding client Takeda Pharmaceutical Company Limited, the largest Japanese pharmaceutical company, on its EUR 9.6 billion (debt free, cash free) acquisition of Swiss drug company Nycomed A/S (“Nycomed”). The deal is subject to competition clearances and is expected to complete within 90 to 120 days.
This is one of the most significant deals to occur in the lifesciences sector this year and the acquisition notably increases Takeda’s footprint and strength in the European market and emerging markets.
Nycomed, headquartered in Zurich, is a privately owned, global pharmaceutical company with a diversified product portfolio including both established prescription pharmaceutical products and over the counter (OTC) products. It employs 12,500 associates worldwide and has affiliates in more than 70 countries.
This complex transaction was led out of the UK by lead partner Sandra Rafferty of the CMS Lifesciences Practice Group and involved seamless coordination between CMS offices in 13 countries including Austria, Belgium, China, France, Germany, Italy, Netherlands, Poland, Russia, Spain, Switzerland and Ukraine. CMS also worked closely with local lawyers in certain markets.
In Germany, a team led by lead partner Dr Christian von Lenthe advised on all aspects of the interdisciplinary deal from the start.
Advisers CMS Hasche Sigle:
Dr Christian von Lenthe, Lead Partner, Germany
Dr Jacob Siebert,
Dr Arne Burmester,
Dr Tim Jonas Haack,
Dr Sebastian Orthmann,
Philipp Weber, (all Corporate)
Dr Anja Hasselmann-Thiede,
Dr Heinz Weidt (both Finance)
Dr Heino Büsching,
Dr Felix Magnus Kessens (both Tax)
Dr Fritz von Hammerstein,
Dr Johanna Raasch (both Environmental)
Carolin Woggon (both Employment)
Dr Nantje Johnston, Pharmaceuticals
Dr Robert Krüger, Real Estate